|
1.
|
Jemal A, Murray T, Ward E, et al: Cancer
statistics, 2005. CA Cancer J Clin. 55:10–30. 2005. View Article : Google Scholar
|
|
2.
|
Gelmann EP: Molecular biology of the
androgen receptor. J Clin Oncol. 20:3001–3015. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Culig Z, Klocker H, Bartsch G and Hobisch
A: Androgen receptors in prostate cancer. Endocr Relat Cancer.
9:155–170. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Prescott J and Coetzee GA: Molecular
chaperones throughout the life cycle of the androgen receptor.
Cancer Lett. 231:12–19. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Heinlein CA and Chang C: Androgen receptor
in prostate cancer. Endocr Rev. 25:276–308. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Chen CD, Welsbie DS, Tran C, et al:
Molecular determinants of resistance to antiandrogen therapy. Nat
Med. 10:33–39. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Isaacs JT and Isaacs WB: Androgen receptor
outwits prostate cancer drugs. Nat Med. 10:26–27. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Masuda Y, Nishida A, Hori K, et al:
Beta-hydroxyisovalerylshikonin induces apoptosis in human leukemia
cells by inhibiting the activity of a polo-like kinase 1 (PLK1).
Oncogene. 22:1012–1023. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Kim SH, Kang IC, Yoon TJ, et al: Antitumor
activities of a newly synthesized shikonin derivative,
2-hyim-DMNQ-S-33. Cancer Lett. 172:171–175. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Masuda Y, Shima G, Aiuchi T, et al:
Involvement of tumor necrosis factor receptor-associated protein 1
(TRAP1) in apoptosis induced by beta-hydroxyisovalerylshikonin. J
Biol Chem. 279:42503–42515. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Yoon Y, Kim YO, Lim NY, Jeon WK and Sung
HJ: Shikonin, an ingredient of Lithospermum erythrorhizon
induced apoptosis in HL60 human premyelocytic leukemia cell line.
Planta Med. 65:532–535. 1999.
|
|
12.
|
Yang H, Zhou P, Huang H, et al: Shikonin
exerts antitumor activity via proteasome inhibition and cell death
induction in vitro and in vivo. Int J Cancer. 124:2450–2459. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Gaddipati JP, Mani H, Shefali, et al:
Inhibition of growth and regulation of IGFs and VEGF in human
prostate cancer cell lines by shikonin analogue 93/637 (SA).
Anticancer Res. 20:2547–2552. 2000.PubMed/NCBI
|
|
14.
|
Wu Z, Wu L, Li L, Tashiro S, Onodera S and
Ikejima T: p53-mediated cell cycle arrest and apoptosis induced by
shikonin via a caspase-9-dependent mechanism in human malignant
melanoma A375-S2 cells. J Pharmacol Sci. 94:166–176. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Chung TW, Moon SK, Chang YC, et al: Novel
and therapeutic effect of caffeic acid and caffeic acid phenyl
ester on hepatocarcinoma cells: complete regression of hepatoma
growth and metastasis by dual mechanism. FASEB J. 18:1670–1681.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Balk SP, Ko YJ and Bubley GJ: Biology of
prostate-specific antigen. J Clin Oncol. 21:383–391. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Burnstein KL: Regulation of androgen
receptor levels: implications for prostate cancer progression and
therapy. J Cell Biochem. 95:657–669. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Rosenfeld MG and Glass CK: Coregulator
codes of transcriptional regulation by nuclear receptors. J Biol
Chem. 276:36865–36868. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Jemal A, Siegel R, Ward E, Murray T, Xu J
and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin. 57:43–66.
2007. View Article : Google Scholar
|
|
20.
|
Nelson WG, De Marzo AM and Isaacs WB:
Prostate cancer. N Engl J Med. 349:366–381. 2003. View Article : Google Scholar
|
|
21.
|
Richter E, Srivastava S and Dobi A:
Androgen receptor and prostate cancer. Prostate Cancer Prostatic
Dis. 10:114–118. 2007. View Article : Google Scholar
|
|
22.
|
Tamura K, Furihata M, Tsunoda T, et al:
Molecular features of hormone-refractory prostate cancer cells by
genome-wide gene expression profiles. Cancer Res. 67:5117–5125.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Sankawa U, Ebizuka Y, Miyazaki T, Isomura
Y and Otsuka H: Antitumor activity of shikonin and its derivatives.
Chem Pharm Bull. 25:2392–2395. 1977. View Article : Google Scholar
|
|
24.
|
Han W, Li L, Qiu S, et al: Shikonin
circumvents cancer drug resistance by induction of a necroptotic
death. Mol Cancer Ther. 6:1641–1649. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Cucciolla V, Borriello A, Oliva A,
Galletti P, Zappia V and Della Ragione F: Resveratrol: from basic
science to the clinic. Cell Cycle. 6:2495–2510. 2007. View Article : Google Scholar : PubMed/NCBI
|
